Journals / Genel Tıp Dergisi / 2017 / Cilt: 27 - Sayı: 1

Periferal lökositlerde CD35, CD46, CD55 ve CD59 düzeyleri

Pages
23–27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Variations of complement regulatory expressions should be kept in mind during investigating endemic diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Complement regulatory proteins prevent the harmful effects of complement activation to the surrounding tissues other than target molecule.
📊
Key Findings & Data:Particularly CD35, CD46, CD55, and CD59 are complement regulatory proteins that are related to diseases.
💡
Conclusion & Impact:Variations of complement regulatory expressions should be kept in mind during investigating endemic diseases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Complement regulatory proteins prevent the harmful effects of complement activation to the surrounding tissues other than target molecule. Particularly CD35, CD46, CD55, and CD59 are complement regulatory proteins that are related to diseases. Many studies were reported infectious, thrombotic, and autoimmune diseases developing due to genetic variations of these proteins. In this study we measured the expression levels of CD35, CD46, CD55, and CD59 on peripheral leucocytes in healthy Turkish population.Materials and Methods: The study was held in 20 healthy volunteers whose ages range from 17 to 39. Blood samples were analysed by flow cytometry within one hour by using CD35, CD46, CD55, and CD59 antibodies. CD35, CD46, CD55, and CD59 positive neutrophils, monocytes, lymphocytes were mentioned as percentages.Results: The highest CD35 level was found on neutrophils (92%), monocytes (84%) and the lymphocytes were the least (17%). CD35 levels were significantly lower on lymphocytes, compared to monocytes and neutrophils (p<0.05). The CD46 level was detected approximately 99% on lymphocytes, monocytes, and neutrophils. The CD55 level was approximately 100% on neutrophils and monocytes whereas it was detected 85% on lymphocytes. CD55 levels were significantly lower on lymphocytes compared to monocytes and neutrophils (p<0.05). The CD59 levels was detected 100% on neutrophils whereas it was detected 70-80% on both lymphocytes and monocytes. CD59 levels were significantly lower on monocytes and lymphocytes compared to neutrophils (p<0.05).Conclusion: Expression of complement regulatory proteins varies within different populations. Variations of complement regulatory expressions should be kept in mind during investigating endemic diseases.

Özet

Giriş: Kompleman aktivasyonunun, hedef molekül dışında bulunan çevre dokulara zarar vermesini kompleman düzenleyici proteinler engeller. Özellikle CD35, CD46, CD55 ve CD59 hastalıklarla ilişkilendirilen kompleman düzenleyici proteinlerdir. Bu proteinlerin genetik varyasyonlarına bağlı olarak enfeksiyon, tromboz, otoimmun hastalıkların oluştuğu bir çok çalışma bulunmaktadır. Çalışmamızda sağlıklı Türk toplumunda periferal lökositlerde CD35, CD46, CD55 ve CD59 proteinlerinin ekspresyon düzeylerini ölçtük.Gereç ve Yöntem: Çalışma yaşları 17-39 arasında değişen, 20 sağlıklı gönüllüde yapıldı. Alınan kan örnekleri CD35, CD46, CD55 ve CD59 antikorları kullanılarak, 1 saat içinde flow sitometrik olarak analiz edildi. CD35, CD46, CD55 ve CD59'u pozitif bulunan nötrofil, monosit ve lenfositler % olarak belirtildi.Bulgular: CD35 düzeyinin en fazla nötrofillerde (%92), monosit (%84) ve en az oranda da lenfositlerde (%17) olduğu gözlendi. CD35 düzeyi lenfositlerde, monosit ve nötrofile göre anlamlı derecede düşük tespit edildi (p<0.05). Lenfosit, monosit ve nötrofillerde CD46 düzeylerinin yaklaşık %99 oranında olduğunu tespit ettik. Nötrofil ve monosit yüzeyinde yaklaşık %100, lenfositlerde %85 oranında CD55 ekspresyonu vardı. CD55 düzeyi lenfositlerde, monosit ve nötrofile göre anlamlı derecede düşük tespit edildi (p<0.05). Nötrofillerin yüzeyinde %100, lenfosit ve monositlerde %70-80 oranında CD59 varlığını tespit ettik. CD59 düzeyinin monosit ve lenfositlerde, nötrofillere göre anlamlı derecede düşük olduğu gözlendi (p<0.05).Sonuç: Kompleman düzenleyici proteinlerin ekspresyonu toplumlara göre değişiklik göstermektedir. Endemik olarak sık görülen hastalıkların etyopatogenezini araştırırken kompleman düzenleyici proteinlerin ekspresyon varyasyonlarının düşünülmesi gereklidir.

🔖

Cite This Article

KURTOĞLU, A. U., UĞUR, S., KOÇTEKİN, B., KARAGÜL, A. (2017). Periferal lökositlerde CD35, CD46, CD55 ve CD59 düzeyleri. Genel Tıp Dergisi, Cilt: 27 - Sayı: 1, 23–27. https://ajindex.com/articles/224827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kristina A. Stoermer, Thomas E. Morrison. Complement and Viral Pathogenesis. Virology 2011; 411: 362-73
  2. Michael C. Carroll. Complement and Humoral Immunity. Vaccine 2008; 26: 128-33
  3. Ricklin D,Hajishengallis G, Yang K et al. Complement - a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-97
  4. Java A, Liszewski MK, Hourcade DE et al. Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney. Mol Immunol 2015;67:584-95
  5. Yamamoto H, Fara AF, Dasgupta P, et al. CD46: the 'multitasker' of complement proteins. Int J Biochem Cell Biol 2013;45:2808-20
  6. Ferrer MF, Scharrig E, Alberdi L, et al. Decay-Accelerating Factor 1 Deficiency Exacerbates Leptospiral-Induced Murine Chronic Nephritis and Renal Fibrosis. PLoS One 2014; 9: e102860
  7. Cai B, Xie S, Liu F, et al.Rapid Degradation of the Complement Regulator, CD59, by a Novel Inhibitor. J Biol Chem 2014; 289:12109-25
  8. Watson R,Wearmouth E, McLoughlin AC, et al. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2015; 63: 287-96
  9. DeZern AE, Brodsky RA.Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia. Hematol Oncol Clin North Am 2015;29:479-94
  10. Cicardi M, Bork K, Caballero T, et al.Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147-57
  11. Wang Q, Zhao HS, Li L. Association between complement factor I gene polymorphisms and the risk of age-related macular degeneration: a Meta-analysis of literature. Int J Ophthalmol 2016;3:298-305
  12. Cockburn IA, Mackinnon MJ, O'Donnell A, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria.Proc Natl Acad Sci U S A. 2004;101:272-7
  13. Kalunian KC, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 2012;64:4040-7
  14. Klaska I, Nowak JZ. The role of complement in physiology and pathology. Postepy Hig Med Dosw (Online) 2007;61:167-77
  15. Melhorn MI, Brodsky AS, Estanislau J, et al. CR1-mediated ATP release by human red blood cells promotes CR1 clustering and modulates the immune transfer process. J Biol Chem 2013;28